Nantahala Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Nantahala Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-200,000	Closed	-$4.32M	–	141
2023 Q4	$4.32M	Hold	200,000	–	–	0.26%	67
2023 Q3	$2.9M	Buy	+200,000	New	+$3.78M	0.25%	78
2022 Q4	–	Sell	-30,000	Closed	-$721K	–	129
2022 Q3	$721K	Buy	+30,000	New	+$673K	0.05%	95
2022 Q1	–	Sell	-200,000	Closed	-$4.38M	–	132
2021 Q4	$4.38M	Buy	+200,000	New	+$3.7M	0.15%	81

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Nantahala Capital Management's SNDX Position: Q3 2025 in Review

Nantahala Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 754,503 shares — an estimated $7.07M sold.

Nantahala Capital Management first reported a position in SNDX in Q3 2020 and held it in 20 quarters. The position peaked at $62.4M in Q4 2021. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

Nantahala Capital Management reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Nantahala Capital Management sold 754,503 Syndax Pharmaceuticals shares in Q3 2025, an estimated $7.07M.
Nantahala Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2020 and held it in 20 quarters.
Nantahala Capital Management's Syndax Pharmaceuticals position peaked at $62.4M in Q4 2021.
227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Nantahala Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.